Verdiva Bio raised $200M in 2025 for next-generation oral GLP-1 receptor agonists designed to match injectable semaglutide efficacy with once-daily oral dosing for obesity and type 2 diabetes.
Verdiva Bio is developing oral small molecule GLP-1 receptor agonists to compete in the massive weight loss and diabetes market dominated by injectable semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). Current oral GLP-1 options like semaglutide tablets have low bioavailability and require fasting, while Verdiva's chemical series aims for significantly higher exposure matching injectable efficacy with a convenient once-daily pill taken without dietary restrictions.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.